Anthrax toxin protective antigen (PrAg) forms a heptamer in which the binding site for lethal factor (LF) spans two adjacent monomers 1, 2 . This suggested that high cell-type specificity in tumor targeting could be obtained using monomers that generate functional LF-binding sites only through intermolecular complementation. We created PrAg mutants with mutations affecting different LF-binding subsites and containing either urokinase plasminogen activator (uPA) or matrix metalloproteinase (MMP) cleavage sites. Individually, these PrAg mutants had low toxicity as a result of impaired LF binding, but when administered together to uPA-and MMPexpressing tumor cells, they assembled into functional LFbinding heteroheptamers. The mixture of two complementing PrAg variants had greatly reduced toxicity in mice and was highly effective in the treatment of aggressive transplanted tumors of diverse origin. These results show that anthrax toxin, and by implication other multimeric toxins, offer excellent opportunities to introduce multiple-specificity determinants and thereby achieve high therapeutic indices.
Anthrax toxin, the major virulence factor of Bacillus anthracis, consists of three polypeptides: PrAg, LF and edema factor (EF) 3 . These three proteins, which are nontoxic individually, can assemble at the mammalian cell surface into toxic complexes. To intoxicate host cells, PrAg binds to its cellular receptors 4, 5 , and is subsequently cleaved by furin or furin-like proteases after the sequence RKKR, allowing the receptorbound C-terminal 63-kDa fragment (PrAg63) to form a ring-shaped heptamer 6, 7 . The oligomerization of PrAg63 provides the binding site for LF and EF 1,2 and triggers internalization of the toxin complex into endosomes, where LF and EF translocate to the cytosol to exert their cytotoxic effects 8, 9 . The unique requirement that PrAg be activated on the target cell surface provides a way to re-engineer this protein to make its activation dependent on proteases that are enriched on the surface of the tumor cells. We have previously generated PrAg proteins requiring activation by either MMP 10 or uPA 11, 12 . Both of these protease systems are overproduced by tumor tissues and are implicated in cancer cell growth and metastasis [13] [14] [15] . The MMP-or uPAactivated PrAg proteins were greatly attenuated in their toxicity to normal tissues and showed potent tumoricidal activities in mice when II   I  III   II   I   III   II   I   II I   II  I  III   II   I   II I   II   I   I   III   II   II  I   II I   II I   II   I  III   II   I   III  II   I   II I   II  I  III   II   I   II I   II I  I   III   II   II  I   II I   II I   II   I  III   II   I   III  II   I   II I   II  I  III   II   I   II  I  II I   I   III   II   II  I   II I   II I   II   I   II I   II   I   III   II   I   III  II   I   II I   II  I  III   II   I   II  I   II   I   I   III  II   II  I II I co-administered with the fusion protein FP59, which consists of anthrax LF amino acids 1-254 fused to the ADP-ribosylation domain of Pseudomonas aeruginosa exotoxin A 16 . Recent studies have shown that LF and EF bind only to the oligomeric form of PrAg63 (ref. 1). It follows that the binding site must span two adjacent monomers. Mutagenesis studies assigned certain PrAg residues involved in LF binding to either of three subsites: subsite I (Arg178) and subsite III (Ile207, Ile210 and Lys214) in the clockwise (right-hand) PrAg63 subunit, and subsite II (Lys197 and Arg200) in the counterclockwise (left-hand) PrAg63 subunit 1,2 ( Fig. 1) . In this report, we have exploited these findings in designing PrAg proteins to achieve high cell-type specificity, using the strategy diagrammed in Figure 1 . The top row shows the assembly of native PrAg63 into a heptamer having functional LF binding sites. The second row shows a PrAg mutant altered in the protease cleavage site so as to be dependent on MMP activity, and containing a second mutation that inactivates LF binding subsite III. Binding of this PrAg to an MMP-expressing cells leads to assembly of a heptamer in which every LF binding site contains the inactivating subsite III mutation. The third row shows a PrAg protein requiring uPA activation and having an inactivating LF binding subsite II mutation. It would also produce an impaired heptamer. However, adding a mixture of these PrAg proteins to a cell having both MMP and uPA activities would generate two PrAg63 proteins that can randomly assemble into a heptamer in which up to three of the LF binding sites would bind LF (the fourth row).
To determine whether two PrAg proteins with mutations in different LF-binding subsites can complement each other (intermolecular complementation) to restore an active LF-binding site, we constructed mutated PrAg proteins PrAg-R200A and PrAg-I210A that contain alanine substitutions at, respectively, the LF-binding subsite II residue Arg200 and the subsite III residue Ile210. These mutated proteins are designated as belonging to groups L and R, respectively, indicating the location of the mutations relative to the monomer-monomer interface. PrAg-200A and PrAg-I210A, just like wild-type PrAg, bound to Chinese hamster ovary (CHO) cells, were processed by furin to produce PrAg63 and formed sodium dodecyl sulfate (SDS)-resistant heptamers (Fig. 2a, top) , but they had significantly decreased LF binding (Fig. 2a, bottom) . However, when PrAg-R200A and PrAg-I210A were applied together to CHO cells, LF-binding ability was substantially regained (Fig. 2a) . Therefore, PrAg-R200A and PrAg-I210A show intermolecular complementation in the formation of LF-binding PrAg heptamers. The decreased LF binding observed for the PrAg-R200A + PrAg-I210A mixture is expected (Fig. 2a) , because the PrAg63 heptamer formed from wildtype PrAg is able to bind three LF molecules 1, 17 , whereas heptamers formed from the complementing PrAg proteins will on average contain fewer than three functional sites (Fig. 1) . In agreement with the results of Figure 2a , cytotoxicity measurements indicated that PrAg-R200A and PrAg-I210A use intermolecular complementation in killing of the mouse macrophage cell line RAW264.7 by LF (Fig. 2b-e) . The mixture of PrAg-R200A + PrAg-I210A had an EC 50 for LF of 0.2 nM (18 ng/ml), 7% and 10% of that of PrAg-R200A (2.7 nM) and PrAg-I210A (2.0 nM) (Fig. 2c-e) , respectively, and approaching the potency found with wild-type PrAg, 0.05 nM (Fig. 2b) .
The apparent affinities of the LF-binding sites present on the PrAg heptamers formed by these mutated PrAg proteins were measured by competitive Schild plot analyses 18, 19 . Cytotoxicity assays were done using as a competitor a mutated, nontoxic LF protein, LF-E687C (ref. 20) , which contains a cysteine substitution at the catalytic site Glu687 (Fig. 2b-f) . Addition of fixed concentrations of LF-E687C shifted the cytotoxicity dose-response curves rightward (Fig. 2b-e) . A reciprocal plot of the midpoints of the dose-response curves yields apparent dissociation constants for the affinity of LF-E687C to the PrAg, R200A + I210A, PrAg-R200A, PrAg-I210A,
LF ( PrAg heptamers (Fig. 2f) . The apparent K d for LF-E687C binding to the complementing mixture of PrAg-R200A and PrAg-I210A is 0.26 nM, which is only 2.5% and 5.5%, those of the individual proteins (10.3 nM for PrAg-R200A, 4.7 nM for PrAg-I210A), respectively, and approaches that of wild-type PrAg, 0.15 nM (Fig. 2f) .
The evidence that intermolecular complementation does occur in this system implied that a PrAg mixture could be created that would be toxic only to cells expressing two distinct cell surface proteolytic activities. To test this proposal, the previously characterized uPAactivated PrAg-U2 (with the furin site RKKR changed to uPA cleavage sequence PGSGRSA) 11, 12 , was further mutated to yield the group L proteins PrAg-U2-K197A and PrAg-U2-R200A (Fig. 1 , Supplementary Table 1 online) . Similarly, the previously described PrAg-L1 protein (with the furin site changed to MMP cleavage sequence GPLGMLSQ) 10 was further mutated to yield the group R proteins PrAg-L1-R178A, PrAg-L1-I210A and PrAg-L1-K214A. PrAg proteins from the L and R groups were added individually and in combination to human melanoma A2058 cells along with the effector FP59. The results showed that the group L protein PrAg-U2-R200A complemented the group R proteins, in particular PrAg-L1-I210A, to efficiently kill A2058 cells in a wide range of molar ratios from 1:5 to 5:1 (Fig. 3a) . In contrast, PrAg-U2-R200A, PrAg-L1-I210A, PrAg-L1-K214A and PrAg-L1-R178A killed r50% of the tumor cells when used alone at high concentrations (7.2 nM), demonstrating that their cytotoxic action is greatly increased by intermolecular complementation. Notably, PrAg-U2-K197A did not complement the proteins in the group R (data not shown). In fact, Lys197 is very close to the LFbinding subsite III residue Lys214 in the PrAg crystal structure. Thus, Lys197 may also be a part of subsite III, so that the Lys197 residues in two adjacent PrAg63 subunits would be required for LF binding. This would also provide another explanation for the ability of the PrAg heptamer to bind a maximum of only three LF or EF molecules 1, 17 .
To verify that the cytotoxicity of a PrAg-U2-R200A + PrAg-L1-I210A mixture is dependent on both uPA and MMP activities, we first showed that, in contrast to wild-type PrAg, PrAg-U2-R200A and PrAg-L1-I210A could not be cleaved by furin (Fig. 3b) , but instead were cleaved only by uPA and MT1 (membrane type 1)-MMP, respectively, to produce PrAg63 (Fig. 3b) . We then further demonstrated that the cytotoxicity of the combination of PrAg-U2-R200A and PrAg-L1-I210A was greatly inhibited by plasminogen activator inhibitor 1 (PAI-1) and by tissue inhibitor 2 of MMP (TIMP-2) (Fig. 3c) , with either one being sufficient, indicating that the toxicity was dependent on the simultaneous expression by the tumor cells of both uPA and MMP activities.
To evaluate the in vivo toxicity of the PrAg proteins described here, various doses of mutated PrAg proteins were injected intraperitoneally (i.p.) into C57BL6 mice at days 0, 3 and 6 in the presence of 3 mg FP59. Wild-type PrAg was very toxic, having a maximum tolerated dose per three injections (MTD3) of 0.25 mg. PrAg-L1 was attenuated by a factor of B16 (MTD3 ¼ 4 mg) and PrAg-U2 by a factor of 40 (MTD3 ¼ 10 mg). The toxicities of PrAg-L1-I210A (MTD3 ¼ 50 mg) and PrAg-U2-R200A (MTD3 Z100 mg) were further decreased by a factor of B10 as compared with that of PrAg-L1 and PrAg-U2, respectively (Supplementary Table 1) . Notably, PrAg-U2-R200A and PrAg-L1-I210A demonstrated an intermolecular complementation in toxicity to mice (MTD3 ¼ 30 + 15 mg) (Supplementary Table 1 ), but the toxicity was substantially lower than those of PrAg-U2 (MTD3 ¼ 10 mg) and PrAg-L1 (MTD3 ¼ 4 mg). To identify the tissues targeted by this mixture, mice were treated i.p. with a combination of 45 mg PrAg-U2-R200A and 22.5 mg PrAg-L1-I210A in the presence of 3 mg FP59 at days 0, 3 and 6 (1.5 Â MTD3). Full necropsy analyses of these mice did not uncover any gross abnormalities. However, extensive histological analyses revealed areas of necrosis in bone and bone marrow ( Supplementary Fig. 1 online) , with no other damage
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Viability found in all other organs and tissues examined (listed in Methods). Mice treated with 1 Â MTD3 showed no outward signs of illness or gross abnormalities, and the localized necrosis in bone and bone marrow was reduced in severity (data not shown). We next evaluated the combination of PrAg-U2-R200A and PrAg-L1-I210A in the treatment of three mouse tumors, B16-BL6 melanoma, T241 fibrosarcoma and LL3 Lewis lung carcinoma. Mice bearing intradermal tumor nodules (0.1-0.8% of body mass) were injected adjacent to the tumor nodules with PBS, 6 mg PrAg-U2-R200A, 6 mg PrAg-L1-I210A or with a combination of 3 mg PrAg-U2-R200A and 3 mg PrAg-L1-I210A in the presence of 0.5 mg FP59 at days 0, 3 and 6. The combination of PrAg-U2-R200A + PrAg-L1-I210A had strong antitumor activity, causing reductions in tumor size of 94% (P o 0.001) in B16-BL6 melanoma, 92% (P o 0.001) for T241 fibrosarcoma and 71% (P o 0.001) for Lewis lung carcinoma, as compared to PBS-treated tumors, at the time when mice were killed (day 8 for melanoma and carcinoma, day 10 for fibrosarcoma) (Fig. 4a-e) . In contrast, the tumors showed little or no response to treatment with the individual proteins. These data demonstrate that the potent tumoricidal activity of these engineered PrAg proteins requires their intermolecular complementation.
To directly compare the antitumor efficacy of this intermolecular complementing mixture with that of PrAg-U2, B16-BL6 tumorbearing mice were treated intradermally (i.d.) with 2 mg or 6 mg of PrAg-U2 or the mixture of PrAg-U2-R200A and PrAg-L1-I210A (1 mg + 1 mg and 3 mg + 3 mg, respectively) in the presence of 0.5 mg FP59 at days 0, 3 and 6. The combination of PrAg-U2-R200A and PrAg-L1-I210A was at least as effective as PrAg-U2 (Fig. 4f) . Given that the MTD3 of PrAg-U2-R200A + PrAg-L1-I210A is 4.5-fold higher than that of PrAg-U2, these data show that the complementing mixture of PrAg-U2-R200A and PrAg-L1-I210A achieves higher tumor specificity. B16-BL6 melanoma-bearing mice were also treated i.p. with the mixture of 20 mg PrAg-U2-R200A and 10 mg PrAg-L1-I210A in the presence of 3 mg FP59 at days 0, 3 and 6 (2/3 MTD3). This systemic treatment significantly reduced tumor growth (60% reduction in size) (P o 0.01), providing results equivalent to those obtained by local administration of 2 mg of the mixture of PrAg-U2-R200A and PrAg-L1-I210A (Fig. 4f) . A moderate body weight loss was observed only in the systemic treatment group (23.9 7 1.5 g before treatment to 21.8 7 1.4 g after treatment, P o 0.05) (Fig. 4g) .
This work establishes proof of principle that anthrax toxin can be re-engineered so that its cytotoxicity relies on two distinct proteolytic activities that are overproduced by tumor tissues, thus achieving enhanced specificity for tumors. The human genome encodes B550 functional proteolytic enzymes, two-thirds of which would be predicted to function in the pericellular environment 21 . Recent highthroughput expression profiling has shown that human tumors present unique molecular 'signatures' in the form of distinct combinations of genes that are consistently overexpressed within a particular tumor type. This also includes pericellular proteases that are expressed by tumor cells in combinations not found in normal tissues [22] [23] [24] [25] [26] . The methodology presented here, therefore, allows the development of engineered toxins with exquisite specificity for certain human tumor types. For example, toxins activated by combinations of hepsin with either matriptase or prostate-specific antigen (PSA) 27 would be predicted to be exceedingly selective for prostate carcinoma.
METHODS

Construction of mutated PrAg proteins.
A modified overlap PCR method was used to construct the two groups of mutated PrAg proteins. The group L included two uPA-activated PrAg proteins, PrAg-U2-K197A and PrAg-U2-R200A, in which LF-binding subsite II residues Lys197 and Arg200 were changed to alanine. The group R contained three MMP-activated PrAg proteins, PrAg-L1-R178A, PrAg-L1-I210A and PrAg-L1-K214A, in which the LF-binding subsite I (Arg178) or subsite III (Ile210 and Lys214) were changed to alanine. To amplify DNA for the group L mutants, PrAg-U2 expression plasmid pYS5-PrAg-U2 (ref. 11) was used as a template. We used a sense primer Pn (5¢-GGTAGATGACCAAGAAGTGA-3¢) and an antisense primer Pk197a (5¢-AAATCCATGGTGAAAGAAAAGTTCTTTTATTTGCGACATCAA CCGTATATCC-3¢; NcoI site is in italic and the antisense codon for Ala197 instead of Lys197 is underlined) to amplify a mutagenic fragment K197A. We used the primer Pn and an antisense primer Pr200a (5¢-AAATCCATGGT GAAAGAAAAGTTGCTTTATTTTTGACATCAACCG-3¢; the antisense codon for Ala200 instead of Arg200 is underlined) to amplify a mutagenic fragment R200A. We used a sense primer Pnco (5¢-TTCACCATGGATTTCTAATATT CATG-3¢; NcoI site is in italic) and an antisense primer Ppst (5¢-TAAATCCTG CAGATACACTCCCACCAAT-3¢; PstI site is in italic) to amplify a fragment designated NP. After digestion by NcoI, the fragments K197A and NP, and R200A and NP, were ligated. The primers Pn and Ppst were used to amplify the ligated products of K197A + NP and R200A + NP, respectively, resulting in the mutagenized fragments U2-K197A and U2-R200A. To amplify the group R mutants, PrAg-L1 expression plasmid pYS5-PrAg-L1 (ref. 10) was used as a template. We used primer Pn and an antisense primer Pr178a-1 (5¢-AGGGATCCCATCATTGTCAGCGTCTGGAACCGTAGGTCC-3¢; BamHI site is in italic and the antisense codon for Ala178 instead of Arg178 is underlined) to amplify a mutagenic fragment R178A-1. We used a sense primer Pr178a-2 (5¢-TGGGATCCCTGATTCATTAGAGGTAGAAGG-3¢; BamHI site is in italic and the codon for Ala178 instead of Arg178 is underlined) and the primer Ppst to amplify a fragment R178A-2. After digestion by BamHI, the fragments R178A-1 and R178A-2 were ligated. The primers Pn and Ppst were used to amplify their ligated product, resulting in the mutagenized fragments L1-R178A.
We used the primer Pn and Ppst to amplify a fragment designated PP. We used a sense primer Pi210a (5¢-TTCACCATGGATTTCTAATGCTCATGAAAA GAAAGG-3¢; NcoI site is in italic and the codon for Ala210 instead of Ile210 is underlined) and an antisense primer Pli4 (5¢-ACGTTTATCTCTTATTAAAAT-3¢) to amplify a mutagenic fragment I210A. We used a sense primer Pk214a (5¢-TTCACCATGGATTTCTAATATTCATGAAAAGGCAGGATTAACCAAATA TA-3¢; NcoI site is in italic and the codon for Ala214 instead of Lys214 is underlined) and the primer Pli4 to amplify a mutagenic fragment K214A. After digestion by NcoI, the fragments I210A and PP, and I214A and PP, were ligated. Primers Pn and Pli4 were used to amplify the ligated products of I210A + PP and I214A + PP, respectively, resulting in the mutagenized fragments L1-I210A and L1-K214A.
The 670-base-pair HindIII/PstI fragments from the digests of U2-K197A, U2-R200A, L1-R178A, L1-I210A and L1-K214A were cloned between the HindIII and PstI sites of pYS5, a wild-type PrAg expression plasmid. The resulting mutated PrAg proteins were accordingly named PrAg-U2-K197A, PrAg-U2-R200A, PrAg-L1-R178A, PrAg-L1-I210A and PrAg-L1-K214A. We also constructed PrAg-R200A and PrAg-I210A, using procedures similar to those just described, except that plasmid pYS5 was used as a template for PCR. The sequences of all mutated PrAg constructs were confirmed by DNA sequencing.
Expression and purification of PrAg proteins. Plasmids encoding the constructs just described were transformed into the nonvirulent strain B. anthracis BH445, and transformants were grown in FA medium 28 with 20 mg/ml kanamycin and 10 mg/ml chloramphenicol for 12 h at 37 1C. The proteins were secreted into the culture supernatants at 20-40 mg/l, precipitated with ammonium sulfate and purified by gel-filtration chromatography to one prominent band at the expected molecular mass of 83 kDa, which comigrated with wild-type PrAg in SDS-PAGE.
Cytotoxicity assays with MTT. Human melanoma A2058 cells were grown and maintained as described 10, 29 . In tumor tissues, cancer cells typically overexpress the uPA receptor (uPAR), whereas either the cancer cells or the adjacent tumor stromal cells express pro-uPA, which is activated on the cancer cell surface after binding to uPAR 14 . A2058 cells express both uPAR and MMP but do not express pro-uPA under the current culture condition 10, 11 . Therefore, pro-uPA was added to mimic the in vivo situation. Cells were cultured in 96-well plates to B50% confluence. Then the cells were preincubated for 30 min with 1.9 nM pro-uPA (American Diagnostica) with or without PAI-1 (46 nM) (American Diagnostica) or TIMP-2 (0.4 mM) (Calbiochem). Various concentrations of PrAg proteins or mixtures of them, combined with FP59 (1.9 nM), were added to the cells to give a total volume of 200 ml/well. Cell viability was assayed after incubation for 48 h using MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) as described 10 .
Mouse macrophage RAW264.7 cells were grown in DMEM with 0.45% glucose, 10% FCS, 2 mM glutamine and 50 mg/ml gentamicin. RAW264.7 cells cultured in 96-well plates to B80% confluence were incubated in medium containing 6 nM of different PrAg proteins or their combinations and various amounts of LF (0-120 nM) for 3.5 h, and then MTT was added to determine cell viability.
PrAg-mediated LF-binding assay. CHO cells grown in 24-well plates were incubated with 12 nM of different PrAg proteins or their combinations and 1.2 nM of LF for 2 h at 37 1C. Then the cells were washed and lysed in a modified RIPA lysis buffer containing protease inhibitors 29 . The cell lysates were analyzed by SDS-PAGE followed by western blotting using a rabbit antiserum specific to PrAg (serum no. 5308, made in our laboratory) to detect PrAg binding and processing, or a rabbit antiserum specific to LF (serum no. 5309, made in our laboratory) to detect LF binding.
In vitro cleavage of PrAg proteins by furin, uPA and MT1-MMP. Reaction mixtures of 50 ml containing 3 mg of the PrAg proteins were incubated at 37 1C with 1 unit of furin (Sigma), 0.3 mg uPA (American Diagnostica) or 0.3 mg soluble MT1-MMP (Calbiochem). Digestion with furin and uPA was carried out as described 11 . Cleavage with MT1-MMP was done in 50 mM HEPES, pH 7.5, 10 mM CaCl 2 , 200 mM NaCl, 0.05% Brij35, 50 mM ZnSO 4 . Aliquots withdrawn at intervals were analyzed by SDS-PAGE, and proteins were visualized by western blot analysis using the rabbit polyclonal antiserum specific to PrAg (serum no. 5308).
Determination of the maximum tolerated doses of recombinant toxins. Male and female C57BL/6J mice (The Jackson Laboratory) aged between 6 and 8 weeks were housed in a pathogen-free facility certified by the Association for Assessment and Accreditation of Laboratory Animal Care International, and the study was carried out in accordance with National Institutes of Health guidelines. The MTD3s of PrAg proteins were determined using a dose escalation protocol aimed at minimizing the number of the mice to be used. The mice (n ¼ 5) in each group were anesthetized by isoflurane inhalation and injected i.p. with three doses of various PrAg proteins combined with 3 mg FP59 in 500 ml PBS at days 0, 3 and 6. The mice were monitored closely for signs of toxicity including inactivity, loss of appetite, inability to groom, ruffling of fur and shortness of breath, and were killed by CO 2 inhalation at the onset of obvious malaise. The MTD3 values were determined as the highest doses in which outward disease was not observed in any mice within a 14-d period of observation. The significance of differences between treatment groups was determined by two-tailed w 2 analysis.
Histopathological analysis. Mice were injected with PBS (n ¼ 3) or the mixture of PrAg-U2-R200A + PrAg-L1-I210A (45/22.5 mg (n ¼ 5) or 30/15 mg (n ¼ 3), in the presence of 3 mg FP59) in PBS at days 0, 3 and 6. At day 7, the mice were killed by a brief CO 2 inhalation. The organs and tissues, including brain, lung, heart, liver, small and large intestines, kidney and adrenal, stomach, pancreata, spleen, thyroid, bladder, esophagus, skeletal muscles, thymus and lymph nodes, were fixed for 24 h in 4% paraformaldehyde, embedded in paraffin, sectioned and stained with H&E and subjected to microscopic analysis by a pathologist unaware of the specific treatments to which they had been subjected.
Tumor transplantation and toxin treatment experiments. The transplanted mouse B16-BL6 melanoma, T241 fibrosarcoma and LL3 Lewis lung carcinoma were established subcutaneously as described 12 . PrAg proteins combined with 0.5 mg FP59 in 100 ml PBS or 100 ml PBS alone were injected i.d. adjacent to the tumor nodule when the tumors had reached a size ranging from B0.1% to 0.8% of total body mass (defined as day 0) and again at days 3 and 6. In a systemic treatment study, B16-BL6 melanoma-bearing mice were treated i.p. with PBS or the mixture of 20 mg PrAg-U2-R200A and 10 mg PrAg-L1-I210A in the presence of 3 mg FP59 at days 0, 3 and 6 (2/3 MTD3). An investigator unaware of treatment group determined the longest and shortest tumor diameter daily using calipers, and the tumor weight was calculated using the formula weight in mg ¼ (length in mm Â [width in mm] 2 )/2 (ref. 30 ). The experiment was terminated when one or more mice in a treatment group presented frank tumor ulceration or the tumor exceeded 10% of body weight. The significance of differences in tumor size was determined by two-tailed Student's t-test.
